GW Pharmaceuticals
| Formerly |
|
|---|---|
| Company type | Subsidiary |
| Nasdaq: GWPH | |
| Industry | Pharmaceutical industry |
| Founded | 1998 |
| Founder |
|
| Headquarters | Cambridge, United Kingdom |
Key people | Justin Gover (CEO) |
| Products |
|
| Revenue | $527 million (2020) |
| -$58 million (2020) | |
| Total assets | $939 million (2020) |
| Total equity | $741 million (2020) |
Number of employees | 1,161 (2020) |
| Parent | Jazz Pharmaceuticals |
| Website | gwpharm |
| Footnotes / references | |
GW Pharmaceuticals Limited is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols (brand name, Sativex) which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.